ARQT Stock: Price, Earnings History and SEC Filings
Arcutis Biotherapeutics, Inc. (ARQT) last traded at $32.07, up 0.31% on the latest session and up 21.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.11 against an analyst estimate of $0.09, a beat of 22.2%.
$32.07 +0.31%
1 month+21.34%
52-week high$33.30
52-week low$19.30
Volume1.88M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ARQT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.11 | $0.09 | +22.22% |
| Mar 2026 | May 6, 2026 | $-0.09 | $-0.02 | -350.00% |
| Dec 2025 | Feb 25, 2026 | $0.13 | $0.03 | +333.33% |
| Sep 2025 | Oct 28, 2025 | $0.06 | $-0.10 | +160.00% |
ARQT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ARQT
SEC filing data is not available right now. You can search for ARQT on SEC EDGAR.
ARQT news
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthOct 28, 2026 · finance.yahoo.com
- Arcutis Appoints Rob Scott, MD to Board of DirectorsOct 28, 2026 · finance.yahoo.com
- Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceOct 27, 2026 · finance.yahoo.com
- Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026Oct 21, 2026 · finance.yahoo.com
- Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbOct 20, 2026 · finance.yahoo.com
- Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics StockOct 19, 2026 · finance.yahoo.com
- Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027Oct 19, 2026 · tikr.com
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) is a US-listed public company on Nasdaq.